MEDP

MEDP

USD

Medpace Holdings Inc. Common Stock

$594.530+8.583 (1.465%)

Precio en Tiempo Real

Healthcare
Diagnostics & Research
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$585.947

Máximo

$599.990

Mínimo

$580.451

Volumen

0.05M

Fundamentos de la Empresa

Capitalización de Mercado

16.7B

Industria

Diagnostics & Research

País

United States

Estadísticas de Negociación

Volumen Promedio

0.34M

Bolsa

NMS

Moneda

USD

Rango de 52 Semanas

Mínimo $250.05Actual $594.530Máximo $625

Noticias Relacionadas

Reuters

Indian pharmacy retailer MedPlus profit jumps with store opening push

Medplus Health Services , one of India's top retail pharmacy chains, reported a 43.3% rise in second-quarter profit on Friday, driven by higher sales from new store openings and steady demand for its private label products.

Ver más
Indian pharmacy retailer MedPlus profit jumps with store opening push
Analyst Upgrades

TD Cowen Maintains Sell on Medpace Hldgs, Raises Price Target to $462

TD Cowen analyst Charles Rhyee maintains Medpace Hldgs with a Sell and raises the price target from $356 to $462.

Ver más
TD Cowen Maintains Sell on Medpace Hldgs, Raises Price Target to $462
Analyst Upgrades

Barclays Maintains Underweight on Medpace Hldgs, Raises Price Target to $485

Barclays analyst Luke Sergott maintains Medpace Hldgs with a Underweight and raises the price target from $425 to $485.

Ver más
Barclays Maintains Underweight on Medpace Hldgs, Raises Price Target to $485
Analyst Upgrades

Mizuho Maintains Outperform on Medpace Hldgs, Raises Price Target to $655

Mizuho analyst Ann Hynes maintains Medpace Hldgs with a Outperform and raises the price target from $575 to $655.

Ver más
Mizuho Maintains Outperform on Medpace Hldgs, Raises Price Target to $655
Analyst Upgrades

Medpace's Q3 Earnings Beat Reflects Robust Growth And Large New Wins

Medpace shares climb as Q3 earnings and revenue top estimates, driven by strong bookings, rising backlog, and an upbeat 2025 guidance.

Ver más
Medpace's Q3 Earnings Beat Reflects Robust Growth And Large New Wins
BusinessWire

Medpace Holdings, Inc. Reports Third Quarter 2025 Results

Revenue of $659.9 million in the third quarter of 2025 increased 23.7% from revenue of $533.3 million for the comparable prior-year period, representing a backlog conversion rate of 23.0%. Net new business awards

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.